Ceylon Hospitals Plc (CHL.N0000) Stock Analysis | Price, Returns, Financials & Key Metrics

Mojo Score Change: Ceylon Hospitals Plc has changed its score on 03 Dec 2025. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Positive results in Mar 25

NET PROFIT(HY) Higher at LKR 579.14 MM
INVENTORY TURNOVER RATIO(HY) Highest at 4.89%
RAW MATERIAL COST(Y) Fallen by 0.3% (YoY)

With ROE of 6.85%, it has a fair valuation with a 0.00 Price to Book Value

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Hospital

Market cap

LKR Million (Small Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.02

Return on Equity

10.52%

Price to Book

0.00

Revenue and Profits:

Net Sales:

2,537 Million

(Quarterly Results - Mar 2025)

Net Profit:

188 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

119.0%

6 Months

140.13%

1 Year

126.71%

2 Years

127.25%

3 Years

137.29%

4 Years

166.1%

5 Years

260.99%

Ceylon Hospitals Plc for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

14.29%

EBIT Growth (5y)

16.62%

EBIT to Interest (avg)

16.20

Debt to EBITDA (avg)

0.47

Net Debt to Equity (avg)

0.17

Sales to Capital Employed (avg)

0.79

Tax Ratio

20.93%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

20.20%

ROE (avg)

8.82%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

0.18

EV to EBITDA

0.14

EV to Capital Employed

0.03

EV to Sales

0.04

PEG Ratio

Dividend Yield

ROCE (Latest)

18.45%

ROE (Latest)

6.85%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 1.40% vs 1.32% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -58.77% vs 445.80% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,536.60",
          "val2": "2,501.60",
          "chgp": "1.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "559.00",
          "val2": "803.40",
          "chgp": "-30.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "52.50",
          "val2": "55.50",
          "chgp": "-5.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "187.70",
          "val2": "455.20",
          "chgp": "-58.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "220.40%",
          "val2": "257.80%",
          "chgp": "-3.74%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 6.46% vs 15.78% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 65.07% vs -30.37% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9,743.90",
          "val2": "9,152.60",
          "chgp": "6.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,110.30",
          "val2": "2,403.90",
          "chgp": "-12.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "252.80",
          "val2": "144.70",
          "chgp": "74.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "102.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "749.10",
          "val2": "453.80",
          "chgp": "65.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "216.60%",
          "val2": "200.70%",
          "chgp": "1.59%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Mar'25

Dec'24

Change(%)

Net Sales

2,536.60

2,501.60

1.40%

Operating Profit (PBDIT) excl Other Income

559.00

803.40

-30.42%

Interest

52.50

55.50

-5.41%

Exceptional Items

0.00

Consolidate Net Profit

187.70

455.20

-58.77%

Operating Profit Margin (Excl OI)

220.40%

257.80%

-3.74%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2025 is 1.40% vs 1.32% in Dec 2024

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is -58.77% vs 445.80% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

9,743.90

9,152.60

6.46%

Operating Profit (PBDIT) excl Other Income

2,110.30

2,403.90

-12.21%

Interest

252.80

144.70

74.71%

Exceptional Items

0.00

102.10

-100.00%

Consolidate Net Profit

749.10

453.80

65.07%

Operating Profit Margin (Excl OI)

216.60%

200.70%

1.59%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 6.46% vs 15.78% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 65.07% vs -30.37% in Mar 2024

All Annual Results

Company CV

About Ceylon Hospitals Plc

Ceylon Hospitals Plc

Hospital

Ceylon Hospitals PLC is a holding company. The Company's Durdans cardiac center offers Cardiac Surgical Intensive Care Unit (CSICU) with over 10 beds, including facilities for pediatric cardiac surgical procedures, Heart Command Center, cardiac catheterization laboratory and a Heart Station. The Company's subsidiaries include Ceylon Hospitals PLC, which is engaged in providing healthcare services; Durdans Heart Surgical Centre (Pvt) Ltd., which is engaged in providing cardiac surgical operations and interventional procedures; Durdans Medical and Surgical Hospital (Pvt) Ltd., which is engaged in providing healthcare services, and Ceygen Biotech (Pvt) Ltd., which is engaged in supplying of molecular biological, biochemical, biotechnological reagents, kits, equipment and accessories for molecular diagnostics and research purpose.

Company Coordinates

Company Details

No.03, Alfred Place, Colombo 03 , COLOMBO None : 03

Tel: 94 11 5410000

https://www.durdans.com

Registrar Details